Recent Updates
Recently added Catalysts
INDV Positive Sentiment Score: 60/100

Indivior Announces Further Changes to Board of Directors Indivior PLC (NASDAQ / LSE: INDV) ( Indivior or the Company ) today announced that, further to the announcement on December 17, 2024 of certain...

Key Takeaway: Indivior PLC has announced additional changes to its Board of Directors following prior appointments and arrangements with Oaktree Capital Management. Key figures, including Dr. David Wheadon, expressed gratitude to outgoing directors for their contributions towards treating opioid use disorder. The company has also revised its Relationship Agreement with Oaktree to reflect these changes. Indivior remains focused on advancing its mission to provide effective treatments for substance use disorders on a global scale.

Market Sentiment Analysis

POSITIVE FACTORS

  • Indivior's board changes may enhance strategic direction.
  • The company has a commitment to opioid use disorder treatment.
  • Indivior is expanding its pipeline for substance use disorder therapies.

Full Press Release Details

RICHMOND, Va. , March 4, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) ("Indivior" or the "Company") today announced that, further to the announcement on December 17, 2024 of certain Director arrangements agreed with Oaktree Capital Management L.P. ("Oaktree"), the announcement on January 28, 2025 of the appointment of Dr. David Wheadon as Chair of the Company, the announcement on February 3, 2025 of the appointment of Daniel Ninivaggi as an Independent Non-Executive Director of the Company, and the announcement on February 27, 2025 of the appointment of Joe Ciaffoni as Chief Executive Officer of the Company, and following further discussions with Oaktree, the Company has agreed to make certain further changes to its Board of Directors (the "Board"):
Dr. David Wheadon , Chair said, " Peter Bains , Jo LeCouilliard and Rob Schriesheim have been unswerving in their support of bringing needed therapeutic interventions to patients suffering from opioid use disorder. I sincerely thank them for the service they have given to Indivior."
In connection with these changes, Indivior and Oaktree have entered into an amended and restated Relationship Agreement, which contains, among other items, customary obligations and undertakings of mutual support.
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD). Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond , VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
SOURCE Indivior PLC

21 %

Frequently Asked Questions

What recent changes were made to Indivior's Board of Directors?

Indivior announced new Board changes in collaboration with Oaktree Capital Management.

Who is the newly appointed CEO of Indivior?

Joe Ciaffoni has been appointed as the CEO of Indivior.

What is Indivior's mission?

Indivior aims to provide evidence-based treatments for substance use disorders.

How many countries offer Indivior's products?

Indivior's portfolio of products is available in over 30 countries.

Where is Indivior headquartered?

Indivior is headquartered in Richmond, VA, United States.

Last updated: Mar 4, 2025